Fox News: How AI is Transforming R&D with Dotmatics
In a Fox News interview, Dotmatics VP of Science Alister Campbell explains how AI and digital transformation are accelerating drug discovery by shortening development timelines, enhancing precision medicine and clinical trials, while emphasizing the continued importance of human expertise in scientific research.
In this Fox News featured interview, Dotmatics VP of Science, Alister Campbell, discusses how AI and digital transformation are accelerating drug discovery and reshaping the future of scientific research. Reflecting on the five-year anniversary of COVID-19’s pandemic declaration, Alister explores how AI-driven insights, collaboration, and automation have helped streamline research and improve patient outcomes.
Key topics include:
- How AI is reducing drug development timelines from a decade to just a few years
- The role of AI in precision medicine and clinical trial optimization
- Why human expertise remains critical in AI-driven research
Related
KRON TV: AI in Medicine From Research Assistant to Predictive Partner
In a KRON-TV interview, Dotmatics VP Phil Mounteney discusses how AI is evolving from a research assistant automating data tasks to a predictive partner that accelerates drug discovery by identifying new targets, designing molecules, and enabling personalized therapies, ultimately reducing costs and time to market while expanding patient access to safer, tailored medicines.
NBC Las Vegas: AI is Accelerating Drug Discovery and Vaccine Development
In an NBC Las Vegas interview, Phil Mounteney, VP of Science and Technology at Dotmatics, explains how AI is transforming drug discovery and vaccine development by accelerating research timelines, reducing costs, enhancing drug safety through advanced data analysis, and optimizing development pipelines for faster and more efficient medical breakthroughs post-COVID.
No big-bang moment: An AI-supported future in pharma will take time
Thomas Swalla, CEO of Dotmatics, discusses in a Fox News article how AI is poised to transform drug discovery by potentially saving billions and speeding up therapy delivery, while emphasizing that despite industry readiness, significant and growing barriers mean progress will be gradual through cumulative small advances rather than an immediate breakthrough.
CBS News: How AI Is Accelerating Safer, More Personalized Drug Discovery
In a CBS News interview, Dotmatics VP Phil Mounteney explains how their internally developed AI models accelerate drug discovery by analyzing early-phase research data to shorten development cycles, reduce costs, and deliver safer, personalized therapies while maintaining data privacy.
Fox News Charlotte: The Use of AI in Drug-making
Fox News Charlotte features Christian Olsen, Vice President of Biologics at Dotmatics, discussing how AI, particularly through the Dotmatics Luma platform, is revolutionizing pharmaceutical drug discovery by reducing costs and accelerating time to market while addressing complex research challenges in laboratories.
Dotmatics on KSNV: The Role of AI in Accelerating the Discovery of Life-Saving Medicines
In a KSNV interview, Phil Mounteney, VP of Science and Technology at Dotmatics, discusses how their AI-ready platform is revolutionizing drug discovery by enabling scientists to develop life-saving medicines more quickly and cost-effectively, potentially reducing drug development timelines from ten years to just a few and advancing personalized medicine.